Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2025-12-25 @ 3:56 AM
NCT ID:
NCT03285802
Brief Summary:
This is an open-label treatment program following basic prescribing information for patients with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and limited treatment alternatives.
Detailed Description:
The objective is to provide access to everolimus for patients with Recurrent UPSC and limited treatment alternatives.
Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
Study:
NCT03285802
Study Brief:
Protocol Section:
NCT03285802